Currently, the NGI Center serves as a hub for several affiliated labs that each approach Alzheimer disease or other neurodegenerative disease for a different angle. Explore the sites below to see what expertise is available through the NGI.

Neurogenomics and Informatics Center Faculties includes PIs that are located on the NGI space at the 4444 Forest Park Ave.

NGI affiliated lab includes any faculty using high-throughput omic data to understand the pathobiology of human with focus on leverage human samples to study neurodegenerative diseases. There is no cost to join, but there are many benefits to becoming an NGI Center Affiliated lab member.

NGI Faculty

Currently, the NGI Center serves as a hub for several affiliated labs that each approach Alzheimer disease or other neurodegenerative disease for a different angle. Explore the sites below to see what expertise is available through the NGI.

Carlos Cruchaga

Specializes in the use of multi-omic technologies across multiple tissue types to deeply characterize neurodegenerative diseases for the identification of biomarkers and therapeutics. Cruchaga Lab

Laura Ibanez

Developing minimally invasive tools for rapid and accurate diagnosis of neurodegenerative diseases during pre-symptomatic phases and prediction of outcomes during the acute phase of ischemic strokes.

Ibanez Lab

Michael Belloy

Understanding the genetics of Alzheimer’s disease and related disorders by employing a multi-modal, big-data approach that integrates genetics, multi-omics, brain imaging (MRI and PET), endophenotypes, clinical findings, and histopathological data. This holistic approach ensures we capture the full spectrum of biologically relevant information to deepen our understanding of the disease.

Belloy lab

Yun Ju Sung

Using multi-tissue multi-omics data in Alzheimer’s disease to identify sex-specific risk genes, prediction models and druggable targets

Sung

Cyril Pottier

Focused on identifying new genetic risk factors and modifiers of early onset dementia using integrative and innovative approaches. Currently combining whole genome sequencing with short and long read single nuclei RNA sequencing to address the variable disease presentation problematic.